Surgical complications in a hemophilia patient with factor VIII inhibitor and their endovascular management.
Hemophilia, an X-linked disorder due to clotting factors VIII or IX deficiency, is associated with recurrent hemorrhage into joints, soft tissue, and organs. Recombinant factor VIII concentrates are available for the treatment of bleeding complications. However, inhibitors to factor VIII develop in 25% to 35% of patients with severe hemophilia A, making the management of bleeding episodes more complex. The treatment of unusual metachronous ruptured aneurysms in a patient with hemophilia A with factor VIII inhibitor is presented, and the outcomes of endovascular and open operations are discussed.
Sadat
Umar
U
Cambridge Vascular Unit, Addenbrooke's Hospital, Cambridge, United Kingdom. sadat.umar@gmail.com
Naik
Jag
J
Hayes
Paul D
PD
D017541:Aneurysm, False / Q000000981:diagnostic imaging / Q000209:etiology / Q000628:therapy*; D015901:Angiography, Digital Subtraction; D001182:Arthroscopy / Q000009:adverse effects*; D001323:Autoantibodies / Q000097:blood*; D003029:Coagulants / Q000627:therapeutic use*; D004621:Embolization, Therapeutic / Q000009:adverse effects*; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000097:blood / Q000150:complications / Q000188:drug therapy* / Q000601:surgery; D006801:Humans; D020244:Infarction, Middle Cerebral Artery / Q000209:etiology / Q000601:surgery; D007719:Knee Joint / Q000098:blood supply; D008297:Male; D008875:Middle Aged; D019106:Postoperative Hemorrhage / Q000209:etiology / Q000517:prevention & control*; D011994:Recombinant Proteins / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000009:adverse effects*; D014711:Vertebral Artery
D001323:Autoantibodies; D003029:Coagulants; D011994:Recombinant Proteins; C078147:F8 protein, human; D005169:Factor VIII